
STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class
He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Alkermes-new-CEO-Blair-Jackson-describes-his-priorities-for-the-company---which-include-a-heavy-focus-on-the-emerging-orexin-agonist-class-e3s5otl
Published
November 10, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#ceoblairjackson #whichinclude #emergingorexinagonist #lifesciences
